The RSI Indicator for BIOX moved out of oversold territory on November 02, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 37 similar instances when the indicator left oversold territory. In 30 of the 37 cases the stock moved higher. This puts the odds of a move higher at 81%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 39 of 62 cases where BIOX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.
The Moving Average Convergence Divergence (MACD) for BIOX just turned positive on November 04, 2026. Looking at past instances where BIOX's MACD turned positive, the stock continued to rise in 29 of 44 cases over the following month. The odds of a continued upward trend are 66%.
Following a +11.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIOX advanced for three days, in 179 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
BIOX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BIOX as a result. In 89 of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIOX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for BIOX entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.220) is normal, around the industry mean (-0.492). P/E Ratio (-0.263) is within average values for comparable stocks, (8.794). Projected Growth (PEG Ratio) (1.236) is also within normal values, averaging (0.867). Dividend Yield (0.000) settles around the average of (0.126) among similar stocks. BIOX's P/S Ratio (0.103) is slightly lower than the industry average of (1.476).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. BIOX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIOX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.
The Moving Average Convergence Divergence (MACD) for FMC turned positive on October 30, 2026. Looking at past instances where FMC's MACD turned positive, the stock continued to rise in 34 of 47 cases over the following month. The odds of a continued upward trend are 72%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where FMC's RSI Oscillator exited the oversold zone, 21 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 58%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on FMC as a result. In 60 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
Following a +4.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where FMC advanced for three days, in 173 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
FMC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 36 of 53 cases where FMC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 68%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FMC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for FMC entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.535) is normal, around the industry mean (-0.492). P/E Ratio (-0.256) is within average values for comparable stocks, (8.794). Projected Growth (PEG Ratio) (1.532) is also within normal values, averaging (0.867). Dividend Yield (0.057) settles around the average of (0.126) among similar stocks. P/S Ratio (0.416) is also within normal values, averaging (1.476).
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. FMC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FMC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.
BIOX | FMC | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 10 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 55 Fair valued | 50 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 95 | 98 | |
PRICE GROWTH RATING 1..100 | 90 | 66 | |
P/E GROWTH RATING 1..100 | 14 | 10 | |
SEASONALITY SCORE 1..100 | 45 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
FMC's Valuation (50) in the Chemicals Agricultural industry is in the same range as BIOX (55) in the Financial Conglomerates industry. This means that FMC’s stock grew similarly to BIOX’s over the last 12 months.
FMC's Profit vs Risk Rating (100) in the Chemicals Agricultural industry is in the same range as BIOX (100) in the Financial Conglomerates industry. This means that FMC’s stock grew similarly to BIOX’s over the last 12 months.
BIOX's SMR Rating (95) in the Financial Conglomerates industry is in the same range as FMC (98) in the Chemicals Agricultural industry. This means that BIOX’s stock grew similarly to FMC’s over the last 12 months.
FMC's Price Growth Rating (66) in the Chemicals Agricultural industry is in the same range as BIOX (90) in the Financial Conglomerates industry. This means that FMC’s stock grew similarly to BIOX’s over the last 12 months.
FMC's P/E Growth Rating (10) in the Chemicals Agricultural industry is in the same range as BIOX (14) in the Financial Conglomerates industry. This means that FMC’s stock grew similarly to BIOX’s over the last 12 months.
| BIOX | FMC | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | 2 days ago 58% |
| Stochastic ODDS (%) | 2 days ago 63% | 2 days ago 68% |
| Momentum ODDS (%) | 2 days ago 86% | 2 days ago 69% |
| MACD ODDS (%) | 2 days ago 66% | 2 days ago 72% |
| TrendWeek ODDS (%) | 2 days ago 87% | 2 days ago 73% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 75% |
| Advances ODDS (%) | 4 days ago 76% | 2 days ago 60% |
| Declines ODDS (%) | 14 days ago 87% | 4 days ago 70% |
| BollingerBands ODDS (%) | 2 days ago 71% | 2 days ago 50% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 72% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIOX’s FA Score shows that 1 FA rating(s) are green while FMC’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIOX’s TA Score shows that 5 TA indicator(s) are bullish while FMC’s TA Score has 5 bullish TA indicator(s).
BIOX (@Chemicals: Agricultural) experienced а -8.17% price change this week, while FMC (@Chemicals: Agricultural) price change was -11.99% for the same time period.
The average weekly price growth across all stocks in the @Chemicals: Agricultural industry was -3.54%. For the same industry, the average monthly price growth was -10.79%, and the average quarterly price growth was -20.52%.
FMC is expected to report earnings on Feb 09, 2027.
The agricultural chemicals sector includes companies that produce chemical products for the agricultural industry applications like crop protection, animal health, biotechnology and pharmaceutical-related products. Some of the largest agricultural chemicals producers include Nutrien Ltd., Corteva Inc., and FMC Corporation.
A.I.dvisor tells us that BIOX and UAN have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BIOX and UAN's prices will move in lockstep.
| Ticker / NAME | Correlation To BIOX | 1D Price Change % | ||
|---|---|---|---|---|
| BIOX | 100% | +9.20% | ||
| UAN - BIOX | 21% Poorly correlated | +0.42% | ||
| SEED - BIOX | 20% Poorly correlated | -2.96% | ||
| IPI - BIOX | 20% Poorly correlated | -1.29% | ||
| FMC - BIOX | 20% Poorly correlated | +0.18% | ||
| SMG - BIOX | 20% Poorly correlated | -0.14% | ||
More | ||||
A.I.dvisor indicates that over the last year, FMC has been loosely correlated with CTVA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if FMC jumps, then CTVA could also see price increases.
| Ticker / NAME | Correlation To FMC | 1D Price Change % | ||
|---|---|---|---|---|
| FMC | 100% | +0.18% | ||
| CTVA - FMC | 41% Loosely correlated | -0.25% | ||
| MOS - FMC | 32% Poorly correlated | -0.83% | ||
| NTR - FMC | 30% Poorly correlated | -0.72% | ||
| IPI - FMC | 22% Poorly correlated | -1.29% | ||
| BIOX - FMC | 20% Poorly correlated | +9.20% | ||
More | ||||